Cells,
Год журнала:
2024,
Номер
13(3), С. 240 - 240
Опубликована: Янв. 26, 2024
Melanoma
frequently
harbors
genetic
alterations
in
key
molecules
leading
to
the
aberrant
activation
of
PI3K
and
its
downstream
pathways.
Although
role
PI3K/AKT/mTOR
melanoma
progression
drug
resistance
is
well
documented,
targeting
pathway
showed
less
efficiency
clinical
trials
than
might
have
been
expected,
since
suppression
PI3K/mTOR
signaling
pathway-induced
feedback
loops
mostly
associated
with
compensatory
pathways
such
as
MAPK/MEK/ERK.
Consequently,
development
intrinsic
acquired
can
occur.
As
a
solid
tumor,
notorious
for
heterogeneity.
This
be
expressed
form
genetically
divergent
subpopulations
including
small
fraction
cancer
stem-like
cells
(CSCs)
non-cancer
stem
(non-CSCs)
that
make
most
tumor
mass.
Like
other
CSCs,
(MSCs)
are
characterized
by
their
unique
cell
surface
proteins/stemness
markers
In
addition
function
robust
marker
stemness
properties,
CD133
crucial
maintenance
properties
resistance.
Herein,
CD133-dependent
regulation
progression,
resistance,
recurrence
reviewed.
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
14
Опубликована: Янв. 4, 2024
Vascular
endothelial
growth
factors
(VEGF),
factor
receptors
(VEGFR)
and
their
downstream
signaling
pathways
are
promising
targets
in
anti-angiogenic
therapy.
They
constitute
a
crucial
system
to
regulate
physiological
pathological
angiogenesis.
In
the
last
20
years,
many
drugs
have
been
developed
based
on
VEGF/VEGFR
treat
diverse
cancers
retinopathies,
new
with
improved
properties
continue
emerge
at
fast
rate.
consist
of
different
molecular
structures
characteristics,
which
enable
them
inhibit
interaction
VEGF/VEGFR,
activity
VEGFR
tyrosine
kinase
(TK),
or
signaling.
this
paper,
we
reviewed
development
marketed
involved
axis,
as
well
some
important
drug
candidates
clinical
trials.
We
discuss
mode
action,
benefits,
current
challenges
that
will
need
be
addressed
by
next-generation
drugs.
focus
characteristics
each
drug,
including
those
approved
only
China.
Cancers,
Год журнала:
2024,
Номер
16(8), С. 1554 - 1554
Опубликована: Апрель 18, 2024
Cancer
is
a
life-threatening
disease
and
one
of
the
leading
causes
death
worldwide.
Despite
significant
advancements
in
therapeutic
options,
most
available
anti-cancer
agents
have
limited
efficacy.
In
this
context,
natural
compounds
with
diverse
chemical
structures
been
investigated
for
their
multimodal
properties.
Curcumin
polyphenol
isolated
from
rhizomes
Curcuma
longa
has
widely
studied
its
anti-inflammatory,
anti-oxidant,
effects.
acts
on
regulation
different
aspects
cancer
development,
including
initiation,
metastasis,
angiogenesis,
progression.
The
phosphatidylinositol-3-kinase
(PI3K)/protein
kinase
B
(AKT)
pathway
key
target
therapy,
since
it
implicated
proliferation,
cell
survival.
found
to
inhibit
PI3K/Akt
tumor
cells,
primarily
via
mediators,
growth
factors,
protein
kinases,
cytokines.
This
review
presents
potential
curcumin
malignancies,
such
as
glioblastoma,
prostate
breast
cancer,
head
neck
cancers,
through
targeting
signaling
pathway.
Cell Biochemistry and Function,
Год журнала:
2024,
Номер
42(1)
Опубликована: Янв. 1, 2024
Abstract
In
recent
years,
the
application
of
engineering
nanomaterials
has
significantly
contributed
to
development
various
biomedical
fields.
Zinc
oxide
(ZnO
NMts)
have
gained
wide
popularity
due
their
biocompatibility,
unique
physical
and
chemical
properties,
stability,
cost‐effectiveness
for
large‐scale
production.
They
emerged
as
potential
materials
anticancer
applications.
This
article
provides
a
comprehensive
review
synthesis
methods
ZnO
NMts
highlights
advantages
combining
with
drugs
nano
platform
cancer
treatment.
Additionally,
briefly
explains
mechanism
action
in
tumor
cells,
focusing
on
mitochondrial
pathways
that
target
cell
apoptosis
autophagy.
It
is
observed
these
are
primarily
influenced
by
reactive
oxygen
species
generated
through
oxidative
stress.
The
discusses
promising
prospects
combined
field
medicine
emphasizes
need
further
in‐depth
research
autophagy
pathways.
Cancers,
Год журнала:
2025,
Номер
17(2), С. 320 - 320
Опубликована: Янв. 20, 2025
Endometrial
cancer
(EC),
a
prevalent
gynecological
malignancy,
presents
significant
challenges
due
to
its
genetic
complexity
and
heterogeneity.
The
genomic
landscape
of
EC
is
underpinned
by
alterations,
such
as
mutations
in
PTEN,
PIK3CA,
ARID1A,
chromosomal
abnormalities.
identification
molecular
subtypes—POLE
ultramutated,
microsatellite
instability
(MSI),
copy
number
low,
high—illustrates
the
diverse
profiles
within
underscores
need
for
subtype-specific
therapeutic
strategies.
integration
multi-omics
technologies
single-cell
genomics
spatial
transcriptomics
has
revolutionized
our
understanding
approach
studying
offers
holistic
perspective
that
enhances
ability
identify
novel
biomarkers
targets.
translation
these
findings
into
personalized
medicine
precision
oncology
increasingly
feasible
clinical
practice.
Targeted
therapies
PI3K/AKT/mTOR
inhibitors
have
demonstrated
potential
improved
treatment
efficacy
tailored
specific
alterations.
Despite
advancements,
persist
terms
variability
patient
responses,
data
workflows,
ethical
considerations.
This
review
explores
underpinnings
EC,
from
genes
It
highlights
ongoing
multidisciplinary
research
collaboration
address
complexities
improve
diagnosis,
treatment,
outcomes.
